Welcome to our dedicated page for Immutep SEC filings (Ticker: IMMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immutep Limited (IMMP) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Immutep submits current reports on Form 6-K under the Securities Exchange Act of 1934, furnishing investors with official information on clinical progress, regulatory interactions, collaborations and financial updates.
Recent Form 6-K filings include press releases on key milestones such as the global TACTI-004 (KEYNOTE-F91) Phase III trial in first-line non-small cell lung cancer, translational and pathologic response data from the EFTISARC-NEO Phase II trial in soft tissue sarcoma, new data from the AIPAC-003 Phase II breast cancer study, and progress in the IMP761 Phase I program for autoimmune diseases. Other filings report on the successful completion of FDA Project Optimus requirements and agreement on the optimal biological dose for eftilagimod alfa, as well as R&D tax incentive payments from the French government and quarterly activities reports.
Through this page, users can follow how Immutep communicates material developments in its LAG-3–focused pipeline, including oncology and autoimmune programs, to the US market. Each 6-K typically incorporates an exhibit containing the full text of a company announcement, such as clinical trial updates, strategic collaborations like the exclusive licensing agreement with Dr. Reddy’s Laboratories for efti in selected territories, or summaries of cash position and R&D spending.
Stock Titan enhances these filings with AI-powered tools that help readers quickly understand the significance of each document. Summaries highlight the core message of new 6-Ks, while structured views make it easier to compare successive disclosures about the same trial or program. Investors can use this page to stay aligned with Immutep’s official SEC record, track the evolution of its clinical and corporate strategy and reference historical filings for deeper due diligence on IMMP.
Immutep Limited furnished a Form 6-K noting that the EFTISARC-NEO Phase II trial evaluating neoadjuvant efti in soft tissue sarcoma met its primary endpoint, with data presented at the ESMO Congress 2025.
The update is provided via Exhibit 99.1. Additional clinical details would be contained in the exhibit presentation materials.
Immutep Limited furnished a Form 6-K reporting an exhibit titled “Immutep Announces Successful Completion of FDA Project Optimus Requirements.” The notice identifies Exhibit 99.1 as the related material and is dated October 13, 2025.
Immutep Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish an exhibit describing a new research collaboration. The exhibit, titled “Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti,” indicates that the company and the George Washington University Cancer Center plan to evaluate neoadjuvant Efti in a cancer setting. This Form 6-K serves as the formal vehicle to provide that collaboration announcement to investors and regulators.